Great Lakes Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Great Lakes Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.39M	Sell	29,800 -18,380	-38%	-$883K	0.01%	479
2026 Q1	$2.49M	Sell	48,180 -4,434	-8%	-$226K	0.02%	374
2025 Q4	$2.61M	Sell	52,614 -18,617	-26%	-$905K	0.02%	373
2025 Q3	$3.4M	Sell	71,231 -70,950	-50%	-$2.86M	0.03%	331
2025 Q2	$4.48M	Sell	142,181 -21,399	-13%	-$686K	0.04%	310
2025 Q1	$5.36M	Sell	163,580 -5,977	-4%	-$212K	0.05%	272
2024 Q4	$6.13M	Buy	+169,557	New	+$5.97M	0.05%	270
2021 Q4	–	Sell	-8,102	Closed	-$216K	–	727
2021 Q3	$216K	Buy	+8,102	New	+$217K	﹤0.01%	640

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Great Lakes Advisors's SUPN Position: Q2 2026 in Review

Great Lakes Advisors reduced its Supernus Pharmaceuticals (SUPN) stake by 38% in Q2 2026, selling an estimated $883K and leaving 29,800 shares worth $1.39M. The position accounts for 0.01% of the portfolio, ranked #479.

Great Lakes Advisors first reported a position in SUPN in Q3 2021 and has held it in 8 quarters since. The position peaked at $6.13M in Q4 2024. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Great Lakes Advisors held 29,800 shares of Supernus Pharmaceuticals worth $1.39M as of Q2 2026.
Great Lakes Advisors sold 18,380 Supernus Pharmaceuticals shares in Q2 2026, an estimated $883K.
Supernus Pharmaceuticals made up 0.01% of Great Lakes Advisors's portfolio in Q2 2026, its #479 holding.
Great Lakes Advisors first reported a position in Supernus Pharmaceuticals in Q3 2021 and has held it in 8 quarters since.
Great Lakes Advisors's Supernus Pharmaceuticals position peaked at $6.13M in Q4 2024.
335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Great Lakes Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.